BR0008759A - Métodos para a produção de proteinas contendo resìduos de cisteina livre - Google Patents

Métodos para a produção de proteinas contendo resìduos de cisteina livre

Info

Publication number
BR0008759A
BR0008759A BR0008759-9A BR0008759A BR0008759A BR 0008759 A BR0008759 A BR 0008759A BR 0008759 A BR0008759 A BR 0008759A BR 0008759 A BR0008759 A BR 0008759A
Authority
BR
Brazil
Prior art keywords
methods
production
cysteine residues
proteins containing
containing free
Prior art date
Application number
BR0008759-9A
Other languages
English (en)
Other versions
BR0008759B1 (pt
Inventor
George N Cox
Daniel H Doherty
Mary S Rosendahl
Original Assignee
Bolder Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22364893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0008759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bolder Biotechnology Inc filed Critical Bolder Biotechnology Inc
Publication of BR0008759A publication Critical patent/BR0008759A/pt
Publication of BR0008759B1 publication Critical patent/BR0008759B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"MéTODOS PARA A PRODUçãO DE PROTEìNAS CONTENDO RESìDUOS DE CISTEìNA LIVRE".A presente invenção se refere a novos métodos de fabricação de proteínas solúveis dotadas de cisteínas livres, nas quais uma célula hospedeira é exposta a um agente bloqueador de cisteína. As proteínas solúveis produzidas por esses métodos podem então ser modificadas. para aumentarem suas efetividades. Essas modificações incluem a ligação de uma metade PEG para a formação de proteínas peguiladas.
BRPI0008759-9A 1999-01-14 2000-01-14 Métodos para a produção de proteinas contendo resíduos de cisteina livre BR0008759B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11604199P 1999-01-14 1999-01-14
US60/116,041 1999-01-14
PCT/US2000/000931 WO2000042175A1 (en) 1999-01-14 2000-01-14 Methods for making proteins containing free cysteine residues

Publications (2)

Publication Number Publication Date
BR0008759A true BR0008759A (pt) 2002-08-06
BR0008759B1 BR0008759B1 (pt) 2014-03-11

Family

ID=22364893

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122013003013A BR122013003013B8 (pt) 1999-01-14 2000-01-14 proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
BRPI0008759-9A BR0008759B1 (pt) 1999-01-14 2000-01-14 Métodos para a produção de proteinas contendo resíduos de cisteina livre

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122013003013A BR122013003013B8 (pt) 1999-01-14 2000-01-14 proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção

Country Status (12)

Country Link
EP (2) EP1144613B2 (pt)
JP (3) JP2002534119A (pt)
KR (1) KR100731826B1 (pt)
CN (1) CN1210400C (pt)
AT (1) ATE526401T1 (pt)
AU (2) AU775937B2 (pt)
BR (2) BR122013003013B8 (pt)
CA (1) CA2359345A1 (pt)
ES (1) ES2373093T3 (pt)
IL (3) IL144259A0 (pt)
NZ (1) NZ513077A (pt)
WO (1) WO2000042175A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL144259A0 (en) 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
DE60129432T2 (de) 2000-05-16 2008-04-17 Bolder Biotechnology, Inc., Louisville Verfahren zur rückfaltung von proteinen mit freien cysteinresten
EP1333036B1 (en) * 2000-10-16 2009-01-21 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
ATE505204T1 (de) 2000-12-20 2011-04-15 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
JP4656814B2 (ja) 2000-12-20 2011-03-23 エフ．ホフマン−ラ ロシュ アーゲー エリスロポエチンコンジュゲート
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
JP2004524020A (ja) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子
MXPA03007316A (es) * 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
MXPA04004809A (es) * 2001-11-20 2004-08-11 Pharmacia Corp Conjugados de hormona de crecimiento humana modificada quimicamente.
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
BR0308710A (pt) * 2002-03-26 2007-01-09 Biosynexus Inc conjugados poliméricos antimicrobianos
EP1382352A1 (de) 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
PA8588901A1 (es) * 2002-11-20 2005-02-04 Pharmacia Corp Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion
PT1667708E (pt) 2002-12-26 2012-09-14 Mountain View Pharmaceuticals Conjugados de interferão-beta-1b e polietileno glicol apresentando uma potência biológica in vitro aumentada
CN102139114A (zh) 2003-02-26 2011-08-03 尼克塔治疗公司 聚合物-因子viii部分缀合物
SE526214C2 (sv) * 2003-02-28 2005-07-26 Amersham Biosciences Ab Ett sätt att generera metallkelaterande affinitetsligander
ATE459647T1 (de) 2003-04-15 2010-03-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
WO2004108667A2 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
WO2005014033A1 (en) * 2003-07-29 2005-02-17 Ares Trading S.A. Use of human growth hormone in multiple system atrophy
WO2005065239A2 (en) * 2003-12-31 2005-07-21 Centocor, Inc. Novel recombinant proteins with n-terminal free thiol
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
HUE033776T2 (en) * 2004-11-12 2018-01-29 Bayer Healthcare Llc FVIII site-specific modification
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
WO2007044083A2 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
KR100735784B1 (ko) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
JP2009537609A (ja) * 2006-05-24 2009-10-29 ノボ ノルディスク ヘルス ケア アーゲー 延長されたｆｉｘアナログ及び誘導体
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
JP5792951B2 (ja) 2010-12-16 2015-10-14 キヤノン株式会社 振動型アクチュエータの制御装置
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP3412314A1 (en) * 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
JP6255348B2 (ja) * 2011-12-19 2017-12-27 ジェンザイム・コーポレーション 甲状腺刺激ホルモン組成物
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
WO2014039010A1 (en) * 2012-09-04 2014-03-13 Republic Polytechnic Isolated oligonucleotides, methods and kits for detection, identification and/or quantitation of chikungunya and dengue viruses
WO2015086853A1 (en) * 2013-12-13 2015-06-18 Novo Nordisk Health Care Ag Method for thioether conjugation of proteins
CA2965414C (en) * 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
SG10201910522TA (en) * 2015-05-15 2020-01-30 Medimmune Llc Improved uricase sequences and methods of treatment
WO2017025897A2 (en) * 2015-08-12 2017-02-16 Pfizer Inc. Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
CN106924754B (zh) * 2015-12-30 2021-11-09 北京大学 聚氨基酸偶联物
EP3580234A1 (en) * 2017-02-08 2019-12-18 Pfizer Inc. Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation
CN111172184A (zh) * 2020-03-10 2020-05-19 大连理工大学 一种基于基因修饰得到人重组干扰素的融合基因、融合蛋白及其制备方法
CN112812963A (zh) * 2021-01-28 2021-05-18 美康生物科技股份有限公司 一种总同型半胱氨酸测试卡
CN115417917A (zh) * 2021-05-30 2022-12-02 中国科学院上海药物研究所 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5016321B1 (pt) * 1969-05-10 1975-06-12
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3540076A1 (de) * 1985-11-12 1987-05-14 Boehringer Mannheim Gmbh Verfahren zur stabilisierung von creatinkinase
JPH01132598A (ja) * 1987-10-14 1989-05-25 Pitman Moore Inc 変性剤溶液中に含まれる組換え蛋白質における分子内ジスルフィド結合の生成を促進する方法
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5130418A (en) * 1989-05-02 1992-07-14 California Biotechnology Inc. Method to stabilize basic fibroblast growth factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5837539A (en) † 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
DE4113750A1 (de) * 1991-04-26 1992-10-29 Boehringer Mannheim Gmbh Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen
CA2116774C (en) * 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
EP0633934A1 (en) † 1992-04-02 1995-01-18 Imperial Cancer Research Technology Limited Modified cells and method of treatment
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
JPH08506095A (ja) * 1992-11-25 1996-07-02 アムジェン ボールダー インコーポレイテッド 改変インシュリン様成長因子
EP0708655A1 (en) 1993-04-07 1996-05-01 Amgen Boulder Inc. Methods of using insulin-like growth factor binding proteins
WO1995011987A1 (en) * 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
JPH10500693A (ja) * 1994-05-24 1998-01-20 アムジエン・ブルダー・インコーポレーテツド 改変型インスリン様増殖因子
EP1211315A1 (en) * 1994-07-29 2002-06-05 Innogenetics N.V. Recombinant vectors for producing HCV envelope proteins
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ATE342278T1 (de) * 1994-10-13 2006-11-15 Amgen Inc Verfahren zur behandlung von diabetes mittels kgf
WO1996036362A1 (en) * 1995-05-16 1996-11-21 Prizm Pharmaceuticals, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
CA2232601A1 (en) * 1995-09-22 1997-03-27 Immunomedics, Inc. Recombinant proteins having multiple disulfide bonds and thiol-substituted conjugates thereof
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU746819B2 (en) * 1997-02-21 2002-05-02 Genentech Inc. Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
IL144259A0 (en) 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
AU2005278903A1 (en) 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
KR20100014215A (ko) 2006-07-07 2010-02-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 신규 단백질 접합체 및 그것의 제조 방법
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
CN105593242B (zh) 2013-07-11 2020-11-06 斯克利普斯研究所 卷曲螺旋免疫球蛋白融合蛋白及其组合物

Also Published As

Publication number Publication date
JP2010280714A (ja) 2010-12-16
CA2359345A1 (en) 2000-07-20
EP1144613A4 (en) 2002-10-29
IL144259A (en) 2009-06-15
AU2004231217A1 (en) 2004-12-23
WO2000042175A1 (en) 2000-07-20
EP2305804B1 (en) 2015-05-06
ES2373093T3 (es) 2012-01-31
EP2305804A1 (en) 2011-04-06
CN1210400C (zh) 2005-07-13
EP1144613A1 (en) 2001-10-17
BR0008759B1 (pt) 2014-03-11
JP5517844B2 (ja) 2014-06-11
BR122013003013B1 (pt) 2015-06-30
NZ513077A (en) 2004-03-26
KR100731826B1 (ko) 2007-06-22
AU2413300A (en) 2000-08-01
IL144259A0 (en) 2002-05-23
KR20020011364A (ko) 2002-02-08
JP2014064594A (ja) 2014-04-17
BR122013003013B8 (pt) 2021-07-06
JP2002534119A (ja) 2002-10-15
EP1144613B2 (en) 2020-05-06
AU775937B2 (en) 2004-08-19
EP1144613B1 (en) 2011-09-28
IL194483A0 (en) 2011-08-01
ATE526401T1 (de) 2011-10-15
CN1355842A (zh) 2002-06-26
AU2004231217B2 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
BR0008759A (pt) Métodos para a produção de proteinas contendo resìduos de cisteina livre
AU7485301A (en) Methods for refolding proteins containing free cysteine residues
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
BR0012243A (pt) Triflúor butenos nematocidas
ATE32728T1 (de) Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel.
DE69010139D1 (de) Haarkräftigungsmittel.
BR0113989A (pt) Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
BR0116024A (pt) Proteìna de fusão heteróloga e uso da mesma
FI964444A (fi) Yhdisteet, jotka sisältävät Michael-akseptorin, erityisesti maleiimi-imidi- tai maleiinihappojohdannaisen, ja jotka on sidottu kromoforiin ja niiden käyttö pitkään kestävissä auringonestokoostumuksissa
MX9202996A (es) Diazabiciclo-(3-3-1)nonanos.
DK0896533T3 (da) Pentafluorbenzensulfonamider og analoger
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
ATE377000T1 (de) 5-ht1f agonisten
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
FI895921A0 (fi) Enzymhaemmande aminosyraderivat, foerfarande foer deras framstaellning, dessa innehaollande aemnen och deras anvaendning.
TR200100125T2 (tr) Çok döngülü tiyazolidin-2-iliden aminleri, bunların üretimi için yöntemler
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
EA200101241A1 (ru) Производные индола
TW200502235A (en) Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof
DE69023559D1 (de) Derivate von Muramyldipeptid.
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
DE60043228D1 (de) Herstellungsverfahren von 2-cyanopyridinen
DE69018816D1 (de) Aminosäurederivate.
DK380289A (da) Fremgangsmaade til ekstraktion af aminosyrer fra vandige oploesninger deraf
DK0408423T3 (da) Beskyttelseskompositioner for metaller, fremgangsmåder til fremstilling deraf og fremgangsmåder til beskyttelse af metaller

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/03/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2549 DE 12-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.